ReviewDrugs2019

Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.

Tessa A Morris et al.PubMed ↗Publisher ↗

No numbers read from the abstract.